Atovaquone-proguanil for treating uncomplicated malaria.
Many conventional treatments for uncomplicated malaria are failing because malaria parasites develop resistance to them. This can be reduced by treating people with combination drugs such as c-proguanil. The review found 10 trials, most of low methodological quality and most funded by a single pharmaceutical company. In addition, trials were small and had few participants thus evidence suggesting atovaquone-proguanil as more effective than a number of single drug treatments at eliminating the Plasmodium falciparum malaria parasite from the blood was limited. There were few good quality data comparing atovaquone-proguanil with other new combination therapies. There were not enough data to assess adverse events, but all trials recorded some adverse events.
Osei-Akoto, A.; Orton, L.C.; Owusu-Ofori, S. Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database of Systematic Reviews (2005) (Issue 4) Art. No.: CD004529. [DOI: 10.1002/14651858.CD004529.pub2]